Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Mar
04
Today In Oncology
Dietary Influence on Leukemia and Lymphoma Progression
Is Advanced Stage Follicular Lymphoma Curable?
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer
AI Model May Predict Cancer Risk in Patients With Colitis-Associated Low-Grade Dysplasia
Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo